G.V.R.K. Sharma
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Boston University (1993–2010); Tufts University (1972); Brigham and Women's Hospital (1974–1993); Biogen (United States) (1993); Northwell Health (2024); United States Department of Veterans Affairs (1973–1994); Feinstein Institute for Medical Research (2024); Harvard University (1973–2012); Veterans Health Administration (1994–2001); Roxbury Community College (1994); Signature Healthcare Brockton Hospital (1992); Veterans of Foreign Wars (1989–2005); VA Boston Healthcare System (2003–2012); Harvard University Press (2006); Beaumont Hospital, Royal Oak (1992)
Faculty Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
G.V.R.K. Sharma's research focuses on investigating factors associated with venous thromboembolic events (VTEs), particularly in patients using Janus Kinase (JAK) inhibitors. Studies examine the impact of pharmacologic anticoagulation on recurrent VTEs in this population, as well as comparing the onset of acute VTEs between different JAK inhibitors like upadacitinib and tofacitinib. Sharma also investigates treatment strategies for inflammatory bowel disease (IBD), including the role of immunomodulators combined with infliximab, utilizing meta-analyses to synthesize findings. Additionally, research has explored gender differences in the authorship of gastroenterology clinical practice guidelines.
Sharma's scholarly work includes 51 publications and has garnered 906 citations, with an h-index of 15. The researcher remains actively publishing, with recent contributions in 2024 and 2025.
Metrics
- h-index: 15
- Publications: 51
- Citations: 910
Selected Publications
-
Gender Differences in the Authorship of Gastroenterology Clinical Practice Guidelines (2025)
-
S1340 Reactive Combination Therapy by Addition of an Immunomodulator to Infliximab Monotherapy Restores Pharmacologic and Clinical Response in Inflammatory Bowel Disease: A Case Series, Systematic Review, and Meta-Analysis (2024)
-
Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis (2024)
-
Earlier onset of acute venous thromboembolism with upadacitinib compared with tofacitinib during Janus kinase inhibitor therapy (2024)
-
Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis (2024)
Collaboration Network
Top Collaborators
- Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis
- Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis
- Earlier onset of acute venous thromboembolism with upadacitinib compared with tofacitinib during Janus kinase inhibitor therapy
- S1340 Reactive Combination Therapy by Addition of an Immunomodulator to Infliximab Monotherapy Restores Pharmacologic and Clinical Response in Inflammatory Bowel Disease: A Case Series, Systematic Review, and Meta-Analysis
- Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis
- Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis
- S1340 Reactive Combination Therapy by Addition of an Immunomodulator to Infliximab Monotherapy Restores Pharmacologic and Clinical Response in Inflammatory Bowel Disease: A Case Series, Systematic Review, and Meta-Analysis
- Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis
- Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis
- Earlier onset of acute venous thromboembolism with upadacitinib compared with tofacitinib during Janus kinase inhibitor therapy
- S1340 Reactive Combination Therapy by Addition of an Immunomodulator to Infliximab Monotherapy Restores Pharmacologic and Clinical Response in Inflammatory Bowel Disease: A Case Series, Systematic Review, and Meta-Analysis
- Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis
- S1340 Reactive Combination Therapy by Addition of an Immunomodulator to Infliximab Monotherapy Restores Pharmacologic and Clinical Response in Inflammatory Bowel Disease: A Case Series, Systematic Review, and Meta-Analysis
- Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis
- S1340 Reactive Combination Therapy by Addition of an Immunomodulator to Infliximab Monotherapy Restores Pharmacologic and Clinical Response in Inflammatory Bowel Disease: A Case Series, Systematic Review, and Meta-Analysis
- Gender Differences in the Authorship of Gastroenterology Clinical Practice Guidelines
- Gender Differences in the Authorship of Gastroenterology Clinical Practice Guidelines
- Gender Differences in the Authorship of Gastroenterology Clinical Practice Guidelines
- Gender Differences in the Authorship of Gastroenterology Clinical Practice Guidelines
- Gender Differences in the Authorship of Gastroenterology Clinical Practice Guidelines
- Gender Differences in the Authorship of Gastroenterology Clinical Practice Guidelines
- Gender Differences in the Authorship of Gastroenterology Clinical Practice Guidelines
- Gender Differences in the Authorship of Gastroenterology Clinical Practice Guidelines
- Gender Differences in the Authorship of Gastroenterology Clinical Practice Guidelines
Similar Researchers
Based on overlapping research topics